Healthy, Obese
Conditions
Keywords
Acute fasting, Inflammatory response, Energy Expenditure
Brief summary
The aim of this study is to investigate the effect of overnight fasting versus a diurnal fasting (during daily life activities) in females with and without obesity on inflammation, neurotrophins, energy metabolism, mood, food cravings, and appetite sensations. This study will be an acute fasting intervention.
Interventions
The volunteers will fast overnight (10 hours) and breakfast will be offered (bread, butter, ham and industrialized fruit juice). The participants will fast for another 10 hours during daily activities.
Sponsors
Study design
Eligibility
Inclusion criteria
* Body mass index between 18.5 and 24.9 kg/m² or equal or greater 35 kg/m²; * Able to sign the informed consent.
Exclusion criteria
* Chronic health conditions (e.g., cancer, renal, heart or liver disorders, and autoimmune diseases), or history of thyroid alterations or use of related medications; * Use of corticosteroids, immunosuppressors, anti-inflammatories, hypoglycemics, medications for weight loss, or any medication known to interfere with metabolic and inflammatory processes (e.g., corticosteroids, nonsteroidal anti-inflammatory drugs); * Previous surgery for weight loss; * Inability to eat any of the components of the standardized breakfast * Pregnancy or breastfeeding; * Smokingç * Alcohol use (\>2 doses/day).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blood glucose | At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours) | Changes in blood glucose will be assessed at baseline and after 10 hours of fasting during daily activities |
| Mood states | At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours) | Changes in anger, confusion, depression, fatigue, tension, and vigor will be assessed using the Brunel Mood Scale |
| Appetite sensations | At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours) | Changes in hunger, satiety, fullness, and prospective food consumption will be assessed at baseline and after 10 hours of fasting during daily activities using a 100 mm visual analogue scale |
| Interleukin 6 | At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours) | Changes in blood interleukin-6 will be assessed at baseline and after 10 hours of fasting during daily activities |
| Lipid panel | At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours) | Changes in lipid panel (i.e. total cholesterol, LDL, HDL and triglycerides) will be assessed at baseline and after 10 hours of fasting during daily activities |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Gastrointestinal peptides | At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours) | Changes in resting energy expenditure will be assessed at baseline and after 10 hours of fasting during daily activities using indirect calorimetry |
| Free fatty acids | At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours) | Changes in free fatty acids will be assessed at baseline and after 10 hours of fasting during daily activities |
| Neurotrophic factors | At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours) | Changes in brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and nerve growth factor (NGF) will be assessed at baseline and after 10 hours of fasting during daily activities |
Other
| Measure | Time frame | Description |
|---|---|---|
| Interleukin 8 | At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours) | Changes in blood interleukin 8 will be assessed at baseline and after 10 hours of fasting during daily activities |
| Tumor necrosis factor-α | At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours) | Changes in tumor necrosis factor-α will be assessed at baseline and after 10 hours of fasting during daily activities |
| Neutrophil/leukocyte ratio (NLR) | At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours) | Changes in NLR will be assessed at baseline and after 10 hours of fasting during daily activities |
| Insulin | At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours) | Changes in insulin will be assessed at baseline and after 10 hours of fasting during daily activities |
| Interleukin 10 | At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours) | Changes in blood interleukin 10 will be assessed at baseline and after 10 hours of fasting during daily activities |
| Resting energy expenditure | At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours) | Changes in resting energy expenditure will be assessed at baseline and after 10 hours of fasting during daily activities using indirect calorimetry |
| High-sensitivity C-reactive protein | At baseline (after overnight fasting) and end (after 10 hours of fasting during the day) of the intervention period (~12 hours) | Changes in blood high-sensitivity C-reactive protein will be assessed at baseline and after 10 hours of fasting during daily activities |
Countries
Brazil